TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sept. 7, 2006--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that it has been awarded a five-year grant from the National Institutes of Health (NIH) as part of the NIH’s Knockout Mouse Project. The goal of the Knockout Mouse Project is to build a comprehensive and broadly available resource of knockout mice to accelerate the understanding of gene function and human diseases. Regeneron will use its VelociGene(R) technology to take aim at 3,500 of the most difficult genes to target and which are not currently the focus of other large-scale knockout mouse programs.
